IceCure Medical (ICCM) said Friday it has received an intention to grant notice from the European Patent Office for its cryoablation technology, which destroys tumors by freezing instead of surgical removal.
The technology was "designed to improve safety and maintain the integrity of cryogen used in the cryoablation procedure," the company said.
The technology was recently given a patent in the US, IceCure said.
The company's were 0.8% higher in recent trading.
Price: 1.24, Change: +0.01, Percent Change: +0.81
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.